Logo image of PVLA

PALVELLA THERAPEUTICS INC (PVLA) Stock Fundamental Analysis

NASDAQ:PVLA - Nasdaq - US6979471090 - Common Stock - Currency: USD

22.93  -0.93 (-3.9%)

Fundamental Rating

3

Overall PVLA gets a fundamental rating of 3 out of 10. We evaluated PVLA against 563 industry peers in the Biotechnology industry. PVLA has a great financial health rating, but its profitability evaluates not so good. PVLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PVLA has reported negative net income.
In the past year PVLA has reported a negative cash flow from operations.
PVLA had negative earnings in each of the past 5 years.
PVLA had a negative operating cash flow in each of the past 5 years.
PVLA Yearly Net Income VS EBIT VS OCF VS FCFPVLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

PVLA has a Return On Assets of -77.74%. This is in the lower half of the industry: PVLA underperforms 68.74% of its industry peers.
Looking at the Return On Equity, with a value of -98.06%, PVLA is in line with its industry, outperforming 45.12% of the companies in the same industry.
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROIC N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
PVLA Yearly ROA, ROE, ROICPVLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PVLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PVLA Yearly Profit, Operating, Gross MarginsPVLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

More info and screens

7

2. Health

2.1 Basic Checks

PVLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PVLA has more shares outstanding
Compared to 5 years ago, PVLA has more shares outstanding
PVLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PVLA Yearly Shares OutstandingPVLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PVLA Yearly Total Debt VS Total AssetsPVLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 12.93 indicates that PVLA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.93, PVLA belongs to the best of the industry, outperforming 90.76% of the companies in the same industry.
PVLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.93
ROIC/WACCN/A
WACC10.12%
PVLA Yearly LT Debt VS Equity VS FCFPVLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 4.82 indicates that PVLA has no problem at all paying its short term obligations.
PVLA has a Current ratio (4.82) which is in line with its industry peers.
A Quick Ratio of 4.82 indicates that PVLA has no problem at all paying its short term obligations.
PVLA has a Quick ratio (4.82) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.82
Quick Ratio 4.82
PVLA Yearly Current Assets VS Current LiabilitesPVLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

PVLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.99%, which is quite impressive.
PVLA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.56%.
PVLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.49% yearly.
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PVLA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.04% on average per year.
Based on estimates for the next years, PVLA will show a very negative growth in Revenue. The Revenue will decrease by -26.21% on average per year.
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y22.64%
EPS Next 5Y13.04%
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.21%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PVLA Yearly Revenue VS EstimatesPVLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 10M 20M 30M 40M
PVLA Yearly EPS VS EstimatesPVLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PVLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PVLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PVLA Price Earnings VS Forward Price EarningsPVLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PVLA Per share dataPVLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as PVLA's earnings are expected to grow with 22.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.38%
EPS Next 3Y22.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PVLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (5/6/2025, 4:40:51 PM)

22.93

-0.93 (-3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31 2025-03-31/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners27.73%
Inst Owner Change3.21%
Ins Owners17.49%
Ins Owner Change105.3%
Market Cap252.69M
Analysts82.67
Price Target50.32 (119.45%)
Short Float %2.29%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-85.23%
Min Revenue beat(4)-100%
Max Revenue beat(4)-43.25%
Revenue beat(8)2
Avg Revenue beat(8)14.08%
Revenue beat(12)4
Avg Revenue beat(12)34.44%
Revenue beat(16)6
Avg Revenue beat(16)33.03%
PT rev (1m)16.08%
PT rev (3m)45.1%
EPS NQ rev (1m)4.21%
EPS NQ rev (3m)-65.38%
EPS NY rev (1m)15.95%
EPS NY rev (3m)18.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-14.33%
Revenue NY rev (3m)-44.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 186.9
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-36
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0.12
BVpS1.48
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.74%
ROE -98.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.7%
ROA(5y)-36.72%
ROE(3y)-100.33%
ROE(5y)-95.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.68%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.82
Quick Ratio 4.82
Altman-Z 12.93
F-Score2
WACC10.12%
ROIC/WACCN/A
Cap/Depr(3y)28.39%
Cap/Depr(5y)118.53%
Cap/Sales(3y)2.48%
Cap/Sales(5y)4.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.01%
EPS Next 2Y38.38%
EPS Next 3Y22.64%
EPS Next 5Y13.04%
Revenue 1Y (TTM)-17.56%
Revenue growth 3Y-17.59%
Revenue growth 5Y0.49%
Sales Q2Q%-100%
Revenue Next Year20.37%
Revenue Next 2Y-97.65%
Revenue Next 3Y-25.99%
Revenue Next 5Y-26.21%
EBIT growth 1Y17.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.9%
EBIT Next 3Y-5.01%
EBIT Next 5Y-21.17%
FCF growth 1Y52.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.68%
OCF growth 3YN/A
OCF growth 5YN/A